Acadia Pharmaceuticals Inc (ACAD) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is held by 331 institutional firms.

• Acadia Pharmaceuticals saw its institutional ownership percentage rose to 100.0% in September 2025 from 99.7% in June 2025.
• The company experienced a -0.39% quarterly change in institutional shares held, alongside an increase of 28.79% in total owners annually.
• During the quarter, 166 institutions bought more Acadia Pharmaceuticals shares, 123 sold shares, and 42 of the 331 total investors held their position steady.
• The total number of shares held by institutions in Acadia Pharmaceuticals decreased to 168.78Mn as of September 2025, a net change of down by 664.87K shares quarter on quarter, and up 13.74Mn shares year over year.
• As of September 30, 2025, BAKER BROS. ADVISORS LP held Acadia Pharmaceuticals's largest shareholding position with over 42.90Mn shares, representing 25.43% of total outstanding shares.
• Among the most significant buyers of Acadia Pharmaceuticals during September 2025 were BRAIDWELL LP (2.38Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.88Mn), MILLENNIUM MANAGEMENT LLC (1.41Mn), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (1.31Mn), STATE STREET CORP (1.08Mn).
• Leading sellers of Acadia Pharmaceuticals stock in September 2025 included MORGAN STANLEY (2.92Mn), RTW INVESTMENTS, LP (1.85Mn), Point72 Asset Management, L.P. (1.69Mn), Assenagon Asset Management S.A. (1.68Mn), Deep Track Capital, LP (1.63Mn).
• The top 10 institutional holders of Acadia Pharmaceuticals for the quarter ending September 2025 included BAKER BROS. ADVISORS LP (42.90Mn), BlackRock, Inc. (20.27Mn), VANGUARD GROUP INC (15.18Mn), STATE STREET CORP (7.26Mn), RTW INVESTMENTS, LP (7.14Mn), GEODE CAPITAL MANAGEMENT, LLC (3.13Mn), DIMENSIONAL FUND ADVISORS LP (2.80Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.48Mn), Palo Alto Investors LP (2.47Mn), BRAIDWELL LP (2.38Mn).